contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


karessa-new-research-and-development-area

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

New area - A wide global market The development will start with midazolam, a pharmaceutical with wide usage in several medical areas. Midazolam is used in several indications where a quick and...

New area - A wide global market  The development will start with midazolam, a pharmaceutical with wide usage in several medical areas. Midazolam is used in several indications where a quick and safe effect is of great value, e.g. to treat epileptic seizures in children, calming and anxiolytic effects in connection to dentist visits and before minor operations.These areas have a wide and huge global market where Karessa midazolam with the unique and convenient administration with a direct and fast absorption from the oral cavity to the bloodstream may achieve a great medical need and at the same time resulting in major commercial benefits to the company. The global children epileptic market only estimated to double the next five years from present 3 billion dollars.(1) The development will start immediately with formulation work. During the first quarter 2019 a planned stabile formulation will enter a preclinical phase. The results will decide the next steps including further development work with international partners.Karessa sees this new area as a very important and positive commercial step to the next phase in development of pharmaceuticals based on the unique platform achieving a major medical need for fast, effective and safe treatment of diseases.The agreement with Uppsalagruppen Medical AB means that Karessa Pharma Holding AB will have an exclusive license during a period of 20 years for usage of substance class bensodiazepines including 32 molecules. Further conditions in the agreement including a royalty of 4 % to Uppsalagruppen Medical AB based on net results of all future sales of products covered in the agreement. The patented trans buccal drug delivery platform This is a Swedish development where the pharmaceutical is administered via a platform similar to a stamp when placed in the buccal mucosa will dissolve during 3-4 minutes releasing the pharmaceutical which is absorbed direct to the bloodstream. It results in a fast, effective and safe distribution of pharmaceuticals, especially in indications where quick relief is prioritized. Today there is no similar product in the market, which means major commercial possibilities for Karessa.1 Global Data 2018 This information is information that Karessa Pharma Holding AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on 28 December 2018.

Karessa - new research and development area

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Nordea Bank

Nordea shareholder? It’s easier than ever to attend the AGM with a new digital set-up

Return on capital (ROE, ROI, ROIC, RONIC)

Balance sheet, debt leverage and risks